Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Oramed Pharmaceuticals (ORMP) Cost of Revenue (2022 - 2025)

Oramed Pharmaceuticals' Cost of Revenue history spans 3 years, with the latest figure at $2.0 million for Q1 2025.

  • For Q1 2025, Cost of Revenue changed N/A year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, changed N/A, while the annual FY2025 figure was $2.0 million, N/A changed from the prior year.
  • Cost of Revenue reached $2.0 million in Q1 2025 per ORMP's latest filing, up from $663000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $2.0 million in Q1 2025 to a low of $184000.0 in Q1 2023.
  • Average Cost of Revenue over 3 years is $637000.0, with a median of $463000.0 recorded in 2022.
  • The largest YoY upside for Cost of Revenue was 43.2% in 2023 against a maximum downside of 68.81% in 2023.
  • A 3-year view of Cost of Revenue shows it stood at $463000.0 in 2022, then skyrocketed by 43.2% to $663000.0 in 2023, then skyrocketed by 199.7% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Cost of Revenue are $2.0 million (Q1 2025), $663000.0 (Q3 2023), and $192000.0 (Q2 2023).